Reliability and validity of measuring temporal muscle thickness as the evaluation of sarcopenia risk and the relationship with functional outcome in older patients with acute stroke

Nozoe, Masafumi; Kubo, Hajime; Kanai, Masashi; Yamamoto, Miho; Okakita, Masaki; Suzuki, Hidetsugu; Shimada, Shinichi; Mase, Kyoshi

doi:10.1016/j.clineuro.2020.106444

Cited by 40 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four studies reported the association between TMT and SAH [ 9 , 21 , 23 , 24 ], two studies between TMT and ICH [ 25 , 26 ], and two studies between TMT and ischemic stroke [ 27 , 28 ]. The other four studies described the standard TMT values [ 18 , 29 ] and the relationship between TMT and nutritional status [ 19 , 20 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Temporal Muscle and Stroke—A Narrative Review on Current Meaning and Clinical Applications of Temporal Muscle Thickness, Area, and Volume

et al. 2022

View full text Add to dashboard Cite

Background: Evaluating muscle mass and function among stroke patients is important. However, evaluating muscle volume and function is not easy due to the disturbances of consciousness and paresis. Temporal muscle thickness (TMT) has been introduced as a novel surrogate marker for muscle mass, function, and nutritional status. We herein performed a narrative literature review on temporal muscle and stroke to understand the current meaning of TMT in clinical stroke practice. Methods: The search was performed in PubMed, last updated in October 2021. Reports on temporal muscle morphomics and stroke-related diseases or clinical entities were collected. Results: Four studies reported on TMT and subarachnoid hemorrhage, two studies on intracerebral hemorrhage, two studies on ischemic stroke, two studies on standard TMT values, and two studies on nutritional status. TMT was reported as a prognostic factor for several diseases, a surrogate marker for skeletal muscle mass, and an indicator of nutritional status. Computed tomography, magnetic resonance imaging, and ultrasonography were used to measure TMT. Conclusions: TMT is gradually being used as a prognostic factor for stroke or a surrogate marker for skeletal muscle mass and nutritional status. The establishment of standard methods to measure TMT and large prospective studies to further investigate the relationship between TMT and diseases are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Nozoe et al [ 28 ] examined 289 acute elderly stroke patients and investigated TMT on CT images as an indicator of sarcopenia risk and its relationship with the functional outcome at three months. They found that sarcopenia risk was independently associated with TMT in older patients with acute stroke.…”

Section: Resultsmentioning

confidence: 99%

Temporal Muscle and Stroke—A Narrative Review on Current Meaning and Clinical Applications of Temporal Muscle Thickness, Area, and Volume

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[7][8][9][10][11] Recently, temporal muscle thickness (TMT) obtained on cranial magnetic resonance images (MRI) has been introduced as a new surrogate marker with which to identify patients at risk of sarcopenia due to its high correlation with the skeletal muscle mass, muscle function and nutritional status. [12][13][14][15][16] These studies suggest that the estimation of skeletal muscle mass can be derived from assessing cranio-facial muscles including TMT directly from brain MRI scans 8 that are routinely obtained for glioblastoma patients.…”

Section: Introductionmentioning

confidence: 99%

Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

Furtner

Weller

Weber

et al. 2022

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To investigate the prognostic relevance of temporal muscle thickness (TMT) as a surrogate parameter of skeletal muscle status in patients with newly diagnosed glioblastoma. Experimental Design: We assessed TMT in cranial MRI of 755 patients enrolled in the CENTRIC EORTC 26071–22072 study (n = 508) and CORE study (n = 247). We used predefined sex-specific TMT cut-off values to categorize “patients at risk of sarcopenia” and “patients with normal muscle status” at baseline. Furthermore, we categorized patients according to the extent of TMT loss over time. Associations with progression-free survival (PFS) and overall survival (OS) were evaluated using the Cox model adjusted for other exploratory variables. Results: Patients at risk of sarcopenia (CENTRIC; n = 158/508, 31.1%; CORE; n = 87/247, 35.2%) at baseline had significantly higher risk of progression and death than patients with normal muscle status in both study cohorts [CENTRIC: PFS = HR 0.16; 95% confidence interval (CI), 0.12–0.21; P < 0.001; OS = HR 0.341; 95% CI, 0.27–0.44; P < 0.001; CORE: PFS = HR 0.29; 95% CI, 0.21–0.39; P < 0.001; OS = HR, 0.365; 95% CI, 0.27–0.49; P < 0.001]. Similar results were obtained in multivariate Cox models adjusted for other important prognostic parameters. The extent of TMT loss over time showed a significant inverse correlation with median OS times in patients at risk for sarcopenia (CENTRIC: P < 0.001; CORE: P = 0.005), but not in patients with normal baseline muscle mass (CENTRIC: P = 0.538; CORE: P = 0.28). Conclusions: TMT identifies ambulatory patients with newly diagnosed glioblastoma at risk for progressive sarcopenia and adverse outcomes. Early intervention may prevent skeletal muscle loss and improve patient outcome.

show abstract

“…Several studies have used the temporal or paravertebral muscle area at cervical vertebra levels (Figure 1). Temporal muscle thickness and area can be measured at the orbital roof level [13][14][15], 5 mm above the level [16,17], or the thickest portion of the temporal muscle [18]. Thickness is measured at the maximum point in the plane, and area is measured manually [16] or automatically [18].…”

Section: Methodsmentioning

confidence: 99%

“…In patients with stroke, temporal muscle thickness at admission was independently associated with sarcopenia, assessed using a questionnaire (β = −0.138; p = 0.02) [14]. In another study, temporal muscle thickness was associated with a poor neurological prognosis at three months, defined as Glasgow Outcome Scale scores of 1-3, in neurocritically ill patients, including those with stroke (adjusted odds ratio (OR), 1.27; 95% confidence interval (CI), 1.028-1.576) [21].…”

Section: Applications In Strokementioning

confidence: 99%

Measuring and Monitoring Skeletal Muscle Mass and Dysfunction After Stroke

Nakanishi¹,

Okura²,

Okamura³

et al. 2021

Preprint

View full text Add to dashboard Cite

Muscle mass at admission is important to survive stroke, and stroke-induced sarcopenia is a serious problem because of its poor prognosis. Muscle mass measurement and monitoring are essential for appropriate re-habilitation and nutrition management. Several methods are used to assess skeletal muscle mass in stroke, such as computed tomography (CT), ultrasonography, bioelectrical impedance analysis, dual-energy X-ray absorptiometry, biomarkers, and anthropometrics. In stroke, a head CT is used to estimate muscle mass by measuring the temporal muscle. However, it is mostly retrospectively conducted due to radiation exposure. After stroke, limb muscle atrophy and diaphragm dysfunction are observed using ultrasound. However, ultrasound requires an understanding of the methods and skill. A bioelectrical impedance analysis can be used to assess muscle mass in patients after a stroke unless they have dynamic fluid changes. Dual-energy X-ray absorptiometry is used for follow-up after hospital discharge. Urinary titin N-fragment and serum C-terminal agrin fragment reflect muscle atrophy after stroke. Anthropometrics may be useful with limited resources. We summarized the features of each measurement and proved the recent evidence to properly measure and monitor skeletal muscle mass after stroke.

show abstract

Reliability and validity of measuring temporal muscle thickness as the evaluation of sarcopenia risk and the relationship with functional outcome in older patients with acute stroke

Cited by 40 publications

References 31 publications

Temporal Muscle and Stroke—A Narrative Review on Current Meaning and Clinical Applications of Temporal Muscle Thickness, Area, and Volume

Temporal Muscle and Stroke—A Narrative Review on Current Meaning and Clinical Applications of Temporal Muscle Thickness, Area, and Volume

Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

Measuring and Monitoring Skeletal Muscle Mass and Dysfunction After Stroke

Contact Info

Product

Resources

About